PDSB
Price
$1.33
Change
+$0.06 (+4.72%)
Updated
Jul 3 closing price
Capitalization
60.79M
40 days until earnings call
STRO
Price
$0.76
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
64.46M
34 days until earnings call
Interact to see
Advertisement

PDSB vs STRO

Header iconPDSB vs STRO Comparison
Open Charts PDSB vs STROBanner chart's image
PDS Biotechnology
Price$1.33
Change+$0.06 (+4.72%)
Volume$141.46K
Capitalization60.79M
Sutro Biopharma
Price$0.76
Change-$0.00 (-0.00%)
Volume$141.88K
Capitalization64.46M
PDSB vs STRO Comparison Chart in %
Loading...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PDSB vs. STRO commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PDSB is a Hold and STRO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (PDSB: $1.33 vs. STRO: $0.76)
Brand notoriety: PDSB and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PDSB: 24% vs. STRO: 11%
Market capitalization -- PDSB: $60.79M vs. STRO: $64.46M
PDSB [@Biotechnology] is valued at $60.79M. STRO’s [@Biotechnology] market capitalization is $64.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PDSB’s FA Score shows that 0 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • PDSB’s FA Score: 0 green, 5 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, both PDSB and STRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PDSB’s TA Score shows that 5 TA indicator(s) are bullish while STRO’s TA Score has 4 bullish TA indicator(s).

  • PDSB’s TA Score: 5 bullish, 5 bearish.
  • STRO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than STRO.

Price Growth

PDSB (@Biotechnology) experienced а -8.28% price change this week, while STRO (@Biotechnology) price change was -4.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

PDSB is expected to report earnings on Aug 13, 2025.

STRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STRO($64.5M) has a higher market cap than PDSB($60.8M). PDSB YTD gains are higher at: -18.405 vs. STRO (-58.522). PDSB has higher annual earnings (EBITDA): -33.08M vs. STRO (-203.18M). STRO has more cash in the bank: 249M vs. PDSB (40M). PDSB has less debt than STRO: PDSB (19M) vs STRO (21.4M). STRO has higher revenues than PDSB: STRO (66.4M) vs PDSB (0).
PDSBSTROPDSB / STRO
Capitalization60.8M64.5M94%
EBITDA-33.08M-203.18M16%
Gain YTD-18.405-58.52231%
P/E RatioN/AN/A-
Revenue066.4M-
Total Cash40M249M16%
Total Debt19M21.4M89%
FUNDAMENTALS RATINGS
PDSB vs STRO: Fundamental Ratings
PDSB
STRO
OUTLOOK RATING
1..100
7451
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6465
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3285

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (26) in the Pharmaceuticals Major industry is in the same range as PDSB (34). This means that STRO’s stock grew similarly to PDSB’s over the last 12 months.

STRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PDSB (100). This means that STRO’s stock grew similarly to PDSB’s over the last 12 months.

PDSB's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as STRO (100). This means that PDSB’s stock grew similarly to STRO’s over the last 12 months.

PDSB's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as STRO (65). This means that PDSB’s stock grew similarly to STRO’s over the last 12 months.

PDSB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as STRO (100). This means that PDSB’s stock grew similarly to STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PDSBSTRO
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FMANF0.10N/A
+0.65%
Freeman Gold Corp.
RBNK23.99N/A
N/A
RiverBank Holding Company
CHUEF12.67N/A
N/A
Chubu Electric Power
MNOIY21.95N/A
N/A
Mandarin Oriental International Ltd.
FNCSF5.10N/A
N/A
North American Financial 15 Split Corp

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with ARCT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+4.72%
ARCT - PDSB
49%
Loosely correlated
+1.17%
RXRX - PDSB
48%
Loosely correlated
+1.15%
DYN - PDSB
45%
Loosely correlated
-2.01%
ATOS - PDSB
45%
Loosely correlated
+1.43%
NRIX - PDSB
44%
Loosely correlated
+2.33%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with ALGS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then ALGS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
-0.10%
ALGS - STRO
44%
Loosely correlated
+7.25%
PDSB - STRO
40%
Loosely correlated
+4.72%
ATXS - STRO
40%
Loosely correlated
+1.40%
TRDA - STRO
40%
Loosely correlated
-0.55%
BEAM - STRO
40%
Loosely correlated
+0.65%
More